<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792714</url>
  </required_header>
  <id_info>
    <org_study_id>DPM-PK-102</org_study_id>
    <nct_id>NCT00792714</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients</brief_title>
  <acronym>DPM-PK-102</acronym>
  <official_title>Determination of the Pharmacokinetics of Inhaled Mannitol After Single and Multiple Dosing in Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of the study is to estimate the systemic pharmacokinetics of mannitol
      after single and multiple dosing of IDPM 400 mg to adult and paediatric cystic fibrosis
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The general objective of the study is to estimate the systemic pharmacokinetics of mannitol after single and multiple dosing of IDPM 400 mg to adult and paediatric cystic fibrosis patients.</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>400mg twice daily for 7 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have given written informed consent to participate in this study in accordance with
             local regulations

          -  Have a confirmed diagnosis of cystic fibrosis (sweat test and/or genotype)

          -  Be aged &gt;6 years (6-11 for paediatrics, 12-17 for adolescents and 18 years for adults)

          -  Have FEV1 &gt; 30 % and &lt; 90% predicted

        Exclusion Criteria:

          -  Be investigators, site personnel directly affiliated with this study, or their
             immediate families. Immediate family is defined as a spouse, parent, child or sibling,
             whether biologically or legally adopted.

          -  Be considered &quot;terminally ill&quot; or listed for lung transplantation

          -  Have had a lung transplant

          -  Be using nebulised hypertonic saline

          -  Have had a significant episode of haemoptysis (&gt; 60 mL) in the three months prior to
             enrolment

          -  Have had a myocardial infarction in the three months prior to enrolment

          -  Have had a cerebral vascular accident in the three months prior to enrolment

          -  Have had major ocular surgery in the three months prior to enrolment

          -  Have had major abdominal, chest or brain surgery in the three months prior to
             enrolment

          -  Have a known cerebral, aortic or abdominal aneurysm

          -  Be breast feeding or pregnant, or plan to become pregnant while in the study

          -  Be using an unreliable form of contraception (female patients at risk of pregnancy
             only)

          -  Be participating in another investigative drug study, parallel to, or within 4 weeks
             of study entry (except inhaled mannitol)

          -  Not able to maintain a mannitol free diet from Day -2 until Day 8 of the treatment
             phase.

          -  Have a known allergy to mannitol

          -  Be using beta blockers

          -  Have uncontrolled hypertension - systolic blood pressure &gt; 190 and / or diastolic
             blood pressure &gt; 100

          -  Have a condition or be in a situation which in the Investigator's opinion may put the
             subject at significant risk, may confound results or may interfere significantly with
             the patient's participation in the study

          -  Be MTT positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mater Adult Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Clinical Foundation</name>
      <address>
        <city>Sheffield</city>
        <zip>S102TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO166YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2008</study_first_submitted>
  <study_first_submitted_qc>November 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2008</study_first_posted>
  <last_update_submitted>January 31, 2010</last_update_submitted>
  <last_update_submitted_qc>January 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Brett Charlton</name_title>
    <organization>Pharmaxis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

